Recce’s Anti-Viral Patent Approved in Hong Kong for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited (ASX: RCE) announced that the Intellectual Property Department of the Hong Kong Special Administrative Region has approved Patent Family 3 “Anti-Virus Agent and Method for Treatment of Viral Infection”, advancing marketing & manufacturing monopolies to February 2037.

The Intellectual Property Department of the Hong Kong Special Administrative Region has approved claims regarding RECCE® 327 (R327) and Anti-Viral formulation RECCE® 529 (R529), particularly:

• Composition/technique of making of RECCE® anti-infectives.
• Usage of R327 or R529 for the cure of viruses with lipid coat.
• Administration of R327 or R529 by oral, injection, inhalation and transdermal dosage applications

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au